In contrast to PD-1/PD-L1 inhibitors, the CTLA-4 inhibitor exhibits a higher propensity to elicit endocrine diseases, skin and subcutaneous tissue disorders, and gastrointestinal disorders, while displaying a comparatively lower propensity to induce cardiac and hematologic and lymphatic diseases (Figure 2A). Here, CTLA4 is linked to lymphatic system disorder.